Cerulean Pharma

Making Nanoparticle-Drug Conjugates (NDCs) designed to target tumors, reduce toxicity, and enable combinations

placeCambridge, Massachusetts, United States calendar_todayFounded 2006 groups20 employees language ceruleanrx.com

Registered entities

Investor mix

7 investors on record; lead investors include Bessemer Venture Partners, Lilly Ventures, Lux Capital, Polaris Partners.

Investor typeCountShare
Venture capital571%
Bank & private debt114%
Other / undisclosed114%
Coming soon